|VENTURE FUNDING TOTAL||$1M|
|Venture Round, 1/05 |
Millennium II Materials Technology Fund
Glycominds, a molecular diagnostics company, develops and commercializes autoimmune and chronic inflammatory disease management tools and services with a distinctive focus on the Multiple Sclerosis market. Their proprietary tests allow physicians to help identify patients at a higher risk for more severe disease outcomes.